Can the Clinical Dementia Rating Scale Identify Mild Cognitive Impairment and Predict Cognitive and Functional

Claudia Woolf1, Melissa J Slavin, Brian Draper

  • 1Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales (UNSW), Sydney, Australia.

Abstract

Insights

The Clinical Dementia Rating Scale (CDR) shows limited use for diagnosing mild cognitive impairment (MCI) but effectively predicts functional decline and dementia risk in older adults.

Area of Science:

  • Gerontology
  • Neurology
  • Cognitive Science

Background:

  • The Clinical Dementia Rating Scale (CDR) is a standard tool for assessing dementia severity.
  • Its effectiveness in diagnosing mild cognitive impairment (MCI) and predicting future cognitive or functional decline is not well-established.

Purpose of the Study:

  • To evaluate the association between CDR scores and expert MCI diagnosis.
  • To determine if baseline CDR scores predict cognitive/functional decline and dementia progression over six years.

Main Methods:

  • A longitudinal study of 733 non-demented adults aged 70-90 years.
  • Collected global and sum of boxes CDR scores, comprehensive neuropsychological/functional assessments, and expert diagnoses at baseline and follow-up.

Main Results:

  • CDR scores demonstrated high specificity but low sensitivity for broadly defined MCI, improving with a narrower definition.
  • Baseline CDR scores predicted functional decline and dementia, but not cognitive change over time.

Conclusions:

  • CDR scores align with MCI only when narrowly defined, indicating it captures more severe MCI cases.
  • All CDR score variations are valuable predictors of functional decline and future dementia incidence.

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
663
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
988
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
804
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K